Nishant C Saxena bought $101k of CRBP
Chief Business Officer at Corbus Pharmaceuticals Holdings, Inc.. 13,500 shares at an average of $7.50, traded Jun 2, 2026, filed Jun 3, 2026.
Score components
- +15RoleOfficer
- +10Trade size$101k at market
- +6Relative to holdingsHoldings up 22%
- +18Price context9% above the 52-week low; 61% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-255834, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | POpen-market purchase Common Stock, par value $0.0001 per share | +4,500 | $7.33 | $33k | 66,300 | Jun 3, 2026 |
| Jun 3, 2026 | POpen-market purchase Common Stock, par value $0.0001 per share | +9,000 | $7.58 | $68k | 75,300 | Jun 3, 2026 |
Related signals
Other insiders at Corbus Pharmaceuticals Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Corbus Pharmaceuticals Holdings, Inc. | Yong Ben director | $16k 2,000 shares | -18% | |
| 33Weak | CRBPbuy Corbus Pharmaceuticals Holdings, Inc. | Nishant C Saxena Chief Business Officer | $25k 2,600 shares | +3% | |
| 24Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $171k 17,000 shares | -10% | |
| 25Weak | Corbus Pharmaceuticals Holdings, Inc. | Sean F. Moran Chief Financial Officer | $121k 12,000 shares | -12% | |
| 15Weak | Corbus Pharmaceuticals Holdings, Inc. | Anne Altmeyer director | $19k 2,412 shares | -24% | |
| 36Weak | Corbus Pharmaceuticals Holdings, Inc. | John Kenneth Jenkins director | $38k 4,800 shares | -56% | |
| 15Weak | Corbus Pharmaceuticals Holdings, Inc. | Winston Kung director | $16k 2,026 shares | -14% | |
| 30Weak | Corbus Pharmaceuticals Holdings, Inc. | Dominic Smethurst Chief Medical Officer | $51k 6,097 shares | -6% | |
| 30Weak | Corbus Pharmaceuticals Holdings, Inc. | Yuval Cohen Chief Executive Officer | $108k 13,871 shares | -7% | |
| 23Weak | Corbus Pharmaceuticals Holdings, Inc. | Sean F. Moran Chief Financial Officer | $37k 4,701 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.